Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmia
Authors:
Journal: Cardiovascular drugs and therapy
Publication Type: Journal Article
Date: 2014
DOI: 10.1007/s10557-014-6548-3
ID: 25112450
Abstract
Ranolazine, an inhibitor of the late current of the cardiac action potential (late I(Na)), is a well established clinical treatment for chronic angina. The late INa in cardiac myocytes also plays an important role in the pathophysiology of acute myocardial ischemia and reperfusion, and thus is a potential therapeutic target to ameliorate consequences of myocardial infarction. In experimental animal models, ranolazine has been shown to reduce myocardial infarct size, improve left ventricular function, decrease ischemia/reperfusion-induced arrhythmias and improve outcome in heart failure. Here we focus specifically on data from in vivo animal studies of myocardial ischemia and reperfusion.
Chemical List
- Acetanilides|||Cardiotonic Agents|||Piperazines|||Ranolazine